[go: up one dir, main page]

HUP0102758A2 - Angiosztatin-kötő protein - Google Patents

Angiosztatin-kötő protein

Info

Publication number
HUP0102758A2
HUP0102758A2 HU0102758A HUP0102758A HUP0102758A2 HU P0102758 A2 HUP0102758 A2 HU P0102758A2 HU 0102758 A HU0102758 A HU 0102758A HU P0102758 A HUP0102758 A HU P0102758A HU P0102758 A2 HUP0102758 A2 HU P0102758A2
Authority
HU
Hungary
Prior art keywords
protein according
angiostatin
antibody
fragment
nucleic acid
Prior art date
Application number
HU0102758A
Other languages
English (en)
Inventor
Lars Holmgren
Boris Troyanovsky
Original Assignee
Pharmacia And Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9802130A external-priority patent/SE9802130D0/xx
Priority claimed from SE9804372A external-priority patent/SE9804372D0/xx
Application filed by Pharmacia And Upjohn Ab filed Critical Pharmacia And Upjohn Ab
Publication of HUP0102758A2 publication Critical patent/HUP0102758A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A találmány megoldást nyújt az angiosztatinnal kapcsolatos korábbiproblémákra (rövid élettartam, gyakori beadás, nagy dózisok), mégpedigegy olyan, <ABP-1< névvel ellátott humán protein segítségével, amelyhumán proteinre az jellemző, hogy hozzá tud kötődni a plazminogénnekegy olyan fragmentumához, előnyösen a plazminogén első négy Kringledoménjéhez (K1-K4), amely fragmentum meghatározó fontosságú azantiangiogén biológiai aktivitás szempontjából. A találmány kiterjed atalálmány szerinti proteint kódoló izolált nukleinsav-molekulára, anukleinsavat tartalmazó vektorra, a vektorral transzformált vagytranszfektált rekombináns sejtre, a találmány szerinti proteinnelspecifikusan kötődő antitestre, az antitestet expresszáló rekombinánssejtre, továbbá a találmány szerinti protein gyógyászati, illetvegyógyszerészeti alkalmazására is. A találmány tárgyát képezi ezenkívülegy szkrínelési eljárás olyan molekulák azonosítására, amelyek képesekkölcsönhatásba lépni a találmány szerinti proteinnel. Ó
HU0102758A 1998-06-15 1999-06-11 Angiosztatin-kötő protein HUP0102758A2 (hu)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8926698P 1998-06-15 1998-06-15
SE9802130A SE9802130D0 (sv) 1998-06-15 1998-06-15 Angiogenesis related molecules
SE9804372A SE9804372D0 (sv) 1998-12-17 1998-12-17 Angiogenesis related molecules
US11438698P 1998-12-29 1998-12-29
PCT/EP1999/004109 WO1999066038A1 (en) 1998-06-15 1999-06-11 Angiostatin-binding protein

Publications (1)

Publication Number Publication Date
HUP0102758A2 true HUP0102758A2 (hu) 2001-11-28

Family

ID=27484811

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102758A HUP0102758A2 (hu) 1998-06-15 1999-06-11 Angiosztatin-kötő protein

Country Status (23)

Country Link
EP (1) EP1088069B1 (hu)
JP (1) JP2002518008A (hu)
KR (1) KR20010052887A (hu)
CN (2) CN1170931C (hu)
AR (1) AR019862A1 (hu)
AT (1) ATE295417T1 (hu)
AU (2) AU769933B2 (hu)
BR (1) BR9911223A (hu)
CA (1) CA2330228A1 (hu)
CY (1) CY1105675T1 (hu)
CZ (1) CZ20004671A3 (hu)
DE (1) DE69925271T2 (hu)
EA (1) EA200100037A1 (hu)
ES (1) ES2242400T3 (hu)
HU (1) HUP0102758A2 (hu)
ID (1) ID28136A (hu)
IL (2) IL139873A0 (hu)
NO (1) NO20006192L (hu)
PL (1) PL344979A1 (hu)
PT (1) PT1088069E (hu)
TR (1) TR200003695T2 (hu)
TW (1) TWI243852B (hu)
WO (1) WO1999066038A1 (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022788A1 (en) 1998-05-19 2004-02-05 Moser Tammy L. Compositions and methods for promoting or inhibiting angiogenesis
WO1999059620A1 (en) 1998-05-19 1999-11-25 Duke University Angiostatin receptor
US20040248138A1 (en) * 2001-11-01 2004-12-09 Mark Shannon Human angiomotin-like protein 1
US7129063B2 (en) 2001-11-16 2006-10-31 Eisai Co., Ltd. Exocrine gland tight junction-constituting protein jeap family
AU2003265559A1 (en) 2002-08-16 2004-03-03 Duke University Identification of the endothelial receptor for the angiostatin kringle-5
GB0330079D0 (en) * 2003-12-20 2004-02-04 Bioinvent Int Ab Vaccine
WO2007110209A1 (en) * 2006-03-29 2007-10-04 Bioinvent International Ab Biological materials and uses thereof
CN104878094B (zh) * 2015-04-30 2019-01-15 北京大北农科技集团股份有限公司 用于检测除草剂耐受性玉米植物dbn9888的核酸序列及其检测方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8501682A (nl) * 1985-06-11 1987-01-02 Tno Nieuw, uit bloed geisoleerd eiwit, werkwijze ter bereiding van dit eiwit, antilichamen tegen het nieuwe eiwit en farmaceutische preparaten, die het eiwit of de antilichamen bevatten.

Also Published As

Publication number Publication date
CZ20004671A3 (cs) 2001-10-17
WO1999066038A1 (en) 1999-12-23
EP1088069A1 (en) 2001-04-04
AR019862A1 (es) 2002-03-20
JP2002518008A (ja) 2002-06-25
CN1626552A (zh) 2005-06-15
PT1088069E (pt) 2005-09-30
DE69925271D1 (de) 2005-06-16
AU2004201999B2 (en) 2007-06-21
ID28136A (id) 2001-05-03
CY1105675T1 (el) 2010-12-22
CN1170931C (zh) 2004-10-13
NO20006192L (no) 2001-02-14
AU769933B2 (en) 2004-02-12
BR9911223A (pt) 2001-03-06
DE69925271T2 (de) 2006-02-23
AU4513499A (en) 2000-01-05
TR200003695T2 (tr) 2001-06-21
AU2004201999A1 (en) 2004-06-10
EA200100037A1 (ru) 2001-06-25
ATE295417T1 (de) 2005-05-15
TWI243852B (en) 2005-11-21
CA2330228A1 (en) 1999-12-23
PL344979A1 (en) 2001-11-19
EP1088069B1 (en) 2005-05-11
IL139873A (en) 2008-08-07
NO20006192D0 (no) 2000-12-06
KR20010052887A (ko) 2001-06-25
CN1305527A (zh) 2001-07-25
ES2242400T3 (es) 2005-11-01
IL139873A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
Waugh et al. The structure of the pro-apoptotic protease granzyme B reveals the molecular determinants of its specificity
Colman et al. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis
Høyer-Hansen et al. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain.
Lovejoy et al. Crystal structures of MMP-1 and-13 reveal the structural basis for selectivity of collagenase inhibitors
Sakai et al. The gamma-carboxyglutamic acid domain of human factor VIIa is essential for its interaction with cell surface tissue factor.
Turk et al. Determination of protease cleavage site motifs using mixture-based oriented peptide libraries
Chen et al. Allosteric disulfide bonds in thrombosis and thrombolysis
Neuenschwander et al. Deletion of the membrane anchoring region of tissue factor abolishes autoactivation of factor VII but not cofactor function. Analysis of a mutant with a selective deficiency in activity.
Abe et al. Evidence for the presence of a latent form of collagenase in human rheumatoid synovial fluid
Pasquini et al. Effects of plasmin on human factor VIII (AHF)
HUP0102758A2 (hu) Angiosztatin-kötő protein
Lord et al. Strategy for recombinant multichain protein synthesis: fibrinogen Bβ-chain variants as thrombin substrates
Hertzberg et al. Construction, expression, and characterization of a chimera of factor IX and factor X. The role of the second epidermal growth factor domain and serine protease domain in factor Va binding.
Renatus et al. Catalytic domain structure of vampire bat plasminogen activator: a molecular paradigm for proteolysis without activation cleavage
Fishelson et al. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b, Bb.
Astermark et al. The epidermal growth factor-like domains of factor IX. Effect on blood clotting and endothelial cell binding of a fragment containing the epidermal growth factor-like domains linked to the gamma-carboxyglutamic acid region
Lin et al. Mutation of lysines in a plasminogen binding region of streptokinase identifies residues important for generating a functional activator complex
Wilhelm et al. Functional properties of the recombinant kringle-2 domain of tissue plasminogen activator produced in Escherichia coli.
Burns et al. Role of cysteine 41 of the A subunit of pertussis toxin
Mullin et al. Decreased lateral aggregation of a variant recombinant fibrinogen provides insight into the polymerization mechanism
Kondo et al. Factor XII Tenri, a novel cross-reacting material negative factor XII deficiency, occurs through a proteasome-mediated degradation
Ayinuola et al. Inactivation of the lysine binding sites of human plasminogen (hPg) reveals novel structural requirements for the tight hPg conformation, M-protein binding, and rapid activation
Bakker et al. The role of the lysyl binding site of tissue-type plasminogen activator in the interaction with a forming fibrin clot
EP1403365A4 (en) PROTEIN-DESTABILIZING POLYPEPTIDE IN CELLS UNDER AEROBIC CONDITIONS AND DNA ENCODING THE POLYPEPTIDE
Wu et al. The binding of plasminogen fragments to cultured human umbilical vein endothelial cells